Obsidian Therapeutics (NASDAQ:OBX) Earns Outperform Rating from Analysts at Lifesci Capital

Lifesci Capital started coverage on shares of Obsidian Therapeutics (NASDAQ:OBX) in a research note released on Tuesday,Benzinga reports. The brokerage issued an outperform rating and a $43.00 price objective on the stock.

Several other research firms have also recently commented on OBX. Piper Sandler started coverage on Obsidian Therapeutics in a research note on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 target price for the company. Zacks Research upgraded Obsidian Therapeutics to a “hold” rating in a research report on Thursday, August 6th. Finally, TD Cowen started coverage on shares of Obsidian Therapeutics in a research report on Thursday, August 6th. They set a “buy” rating on the stock. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Obsidian Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $42.50.

Obsidian Therapeutics Stock Performance

OBX stock opened at $20.19 on Tuesday. Obsidian Therapeutics has a fifty-two week low of $14.57 and a fifty-two week high of $49.97.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.